PHARMARON：2025FIRSTQUARTERLYREPORT.pdf

1、1Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement,make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in relia

2、nce upon the whole or any part of the contents of this announcement.Pharmaron Beijing Co.,Ltd.康龍化成(北京)新藥技術股份有限公司(A joint stock company incorporated in the Peoples Republic of China with limited liability)(Stock Code:3759)2025 FIRST QUARTERLY REPORTThis announcement is made by Pharmaron Beijing Co.,L

3、td.(the“Company”and together with its subsidiaries,the“Group”)pursuant to Rules 13.09 and 13.10B of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions(as defined in the Listing Rules)under Part XIVA of the Securities and Fut

4、ures Ordinance(Chapter 571 of the Laws of Hong Kong).The following is the first quarterly report for 2025 of the Company.The financial data contained in this quarterly report is,except for section(IV)in Part IV which has been prepared in accordance with the International Financial Reporting Standard

5、s issued by the International Accounting Standard Board(the“IFRSs”)or as otherwise indicated,prepared in accordance with the PRC Accounting Standards for Business Enterprises.The first quarterly report for 2025 of the Company has not been audited.By order of the BoardPharmaron Beijing Co.,Ltd.康龍化成(北

6、京)新藥技術股份有限公司Dr.Lou BoliangChairmanBeijing,the PRCApril 27,2025As at the date of this announcement,the Board of Directors comprises Dr.Lou Boliang,Mr.Lou Xiaoqiang and Ms.Zheng Bei as executive Directors;Mr.Hu Baifeng and Mr.Li Jiaqing as non-executive Directors;Ms.Li Lihua,Mr.Tsang Kwan Hung Benson